MdxHealth : MDxHealth to Present at the 2013 BIO CEO & Investor Conference IRVINE, CA, and LIEGE, BELGIUM - February 4, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer diagnosis and treatment, today announced that Dr. Jan Groen , the Company's Chief Executive Officer, will present at the 15^th Annual BIO CEO & Investor Conference on Monday, February 11th 2013 at 3.00 pm Eastern Time at the Waldorf-Astoria in New York, NY. About the BIO CEO & Investors Conference The Annual BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. This year's conference will feature corporate presentations from more than 130 leading biotechnology and pharmaceutical companies. The presenting companies consist of a selection of mid- to large-cap established public companies from around the globe, who typically have a clinical stage program centered around therapeutics, molecular diagnostics, or a platform technology, as well as an upcoming clinical, regulatory, or corporate catalyst. More information on the conference can be found at www.bio.org. About MDxHealth MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. The company's first commercial product, the ConfirmMDx for Prostate Cancer test, has been shown to help distinguish patients who have a true-negative biopsy from those who may have occult cancer. MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. The company has a proprietary platform and a strong epigenetic product pipeline focused on the development of products for brain and lung cancers. The company is based in Irvine, California with a European headquarters in Liege, Belgium. For more information visit MDxHealth website at www.mdxhealth.com. Contacts Company : Dr Jan Groen, CEO MDxHealth US: +1 949 812 6979 BE: +32 4 364 20 70 email@example.com Media : Mike Sinclair Halsin Partners UK: +44 20 7318 2955 US: +1 646 378 2952 Cell: +44 7968 022075 firstname.lastname@example.org Investors : Seth Lewis The Trout Group US : + 1 646 378 2952 email@example.com This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. BIO CEO ENG ------------------------------------------------------------------------------ This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: MdxHealth via Thomson Reuters ONE HUG#1675036
MdxHealth : MDxHealth to Present at the 2013 BIO CEO & Investor Conference
Press spacebar to pause and continue. Press esc to stop.